B Vitamins Reduce Homocysteine, But Not Disease in Diabetic Patients
G. Douglas Andersen, DC, DACBSP, CCN
Whenever the topic of kidney disease arises in my practice, the first thought that crosses my mind is diabetes, since almost 40 percent will eventually have kidney problems.1 There is evidence of a correlation between homocysteine levels in diabetic patients and diseases of the kidneys, heart and eyes.2 To lower homocysteine, we have a powerful, proven way to do it with three members of the B vitamin family.3 Many health care professionals have reasonably concluded that lowering homocysteine lowers the risk, degree or progression of secondary problems often seen in patients with diabetes.
Homocysteine: What Is Normal?
Normal plasma homocysteine values vary widely between labs and can range from as low as 2.2 to as high as 17 micromoles per liter (abbreviated as mcmol/L or umol/L). Homocysteine increases with age and runs ~1.5 umol/L higher in males than females. There is a debate on what is optimal, and this too is affected by gender and age. In general, "optimal homocysteine" ranges run from less than 10 to under 6 umol/L.
The DIVINe Study
The Diabetic Intervention with Vitamins to Improve Nephropathy (DIVINe) study followed a screened group of diabetic patients with kidney disease for three years. Those who met the criteria had diabetic nephropathy, but their condition was not considered advanced.4 The 238 subjects who qualified were divided into two groups. One took 2,500 mcg of folic acid, 1,000 mcg of vitamin B12, and 25 mg of vitamin B6 a day. The second group took a look-alike placebo. Eighty-three percent of the patients were white male, 81 percent had type 2 (as opposed to type 1) diabetes, and their mean age was 60. Plasma homocysteine levels at baseline were 16.4 umol/L and 14.7 umol/L in the placebo and B-vitamin groups, respectively.
Results
In approximately three years of follow-up, the B-vitamin group had mean homocysteine levels decline from 14.7 umol/L to 12.5 umol/L, while those assigned to placebo had their averages increase from 16.4 umol/L to 19 umol/L. However, the B-vitamin group also had an accelerated rate of GFR decrease, more strokes and more heart attacks. [See table]
A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant, 2008;23(4):1216-23.
Building on a historic March 2026 meeting between Make America Healthy Again and chiropractic leadership, MAHA has announced the launch of the MAHA Chiropractic Hub, “a coordinated national partnership uniting MAHA Center, MAHA Action, and the chiropractic profession, including national associations, state organizations, practitioners, educators, researchers, and patient advocates. The Chiropractic Hub will advance federal policy, expand patient access, and build broad public support for chiropractic care across America.”
The chiropractic profession is confronting one of the most significant federal regulatory threats it has faced in decades. A new U.S. Department of Education (ED) accountability framework – commonly referred to as the “Do No Harm” (DNH) regulation – could place many chiropractic programs at risk of losing access to federal financial aid (student loans), potentially reshaping the future of chiropractic education and workforce development across the United States.
Pain has become the dominant language of musculoskeletal healthcare. Numeric pain-rating scales and symptom reports are routinely used as primary indicators of clinical success. But while pain reduction is meaningful, it is an incomplete and often misleading representation of recovery. This has real consequences for patient adherence, long-term outcomes, and how conservative care is perceived within the broader healthcare system.
